These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 25820533)

  • 21. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey.
    Willis WD; Diago-Cabezudo JI; Madec-Hily A; Aslam A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):123-30. PubMed ID: 23402452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
    Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
    Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.
    Alvarez CA; Lingvay I; Vuylsteke V; Koffarnus RL; McGuire DK
    Clin Pharmacol Ther; 2015 Aug; 98(2):145-61. PubMed ID: 25963811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes.
    Razavi-Nematollahi L; Ismail-Beigi F
    Curr Diab Rep; 2019 Nov; 19(11):132. PubMed ID: 31748838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. State of safety.
    Tsai A
    Diabetes Forecast; 2015; 68(4):60-2, 65. PubMed ID: 26373221
    [No Abstract]   [Full Text] [Related]  

  • 28. The benefits and risks of new therapies for type 2 diabetes.
    Asche CV; Nelson RE
    J Manag Care Pharm; 2008 Sep; 14(7):655-7. PubMed ID: 18774876
    [No Abstract]   [Full Text] [Related]  

  • 29. In T2DM, periconceptional, noninsulin, second-line antidiabetes medications were not linked to major congenital malformations vs. insulin.
    Egan AM
    Ann Intern Med; 2024 Apr; 177(4):JC47. PubMed ID: 38560907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood glucose levels during acute illness can help predict future diabetes risk.
    Cardiovasc J Afr; 2015; 26(6):250. PubMed ID: 26659437
    [No Abstract]   [Full Text] [Related]  

  • 31. Incidence of breast cancer in women with type 2 diabetes.
    Burki TK
    Lancet Oncol; 2016 Dec; 17(12):e523. PubMed ID: 28100436
    [No Abstract]   [Full Text] [Related]  

  • 32. An update on the comparative effectiveness and safety of medications for type 2 diabetes.
    Goldstein MR; Mascitelli L
    Ann Intern Med; 2011 Oct; 155(8):562-3; author reply 563. PubMed ID: 22007052
    [No Abstract]   [Full Text] [Related]  

  • 33. Promising Safety Profile of Noninsulin Medications for Type 2 Diabetes in Early Pregnancy.
    Ghaffari N
    JAMA Intern Med; 2024 Feb; 184(2):152-153. PubMed ID: 38315209
    [No Abstract]   [Full Text] [Related]  

  • 34. Regarding the survey on perioperative diabetes medications and glucose control.
    Raghuraman MS
    Can J Anaesth; 2020 Jan; 67(1):154-155. PubMed ID: 31190142
    [No Abstract]   [Full Text] [Related]  

  • 35. In reply: Regarding the survey on perioperative diabetes medications and glucose control.
    Brown R; Siddiqui U; Paul J
    Can J Anaesth; 2020 Jan; 67(1):156-157. PubMed ID: 31175612
    [No Abstract]   [Full Text] [Related]  

  • 36. The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future.
    Bailey CJ
    Clin Pharmacol Ther; 2015 Aug; 98(2):170-84. PubMed ID: 25963904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type 2 diabetes mellitus in older adults: clinical considerations and management.
    Bellary S; Kyrou I; Brown JE; Bailey CJ
    Nat Rev Endocrinol; 2021 Sep; 17(9):534-548. PubMed ID: 34172940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Compared benefits of educational programs dedicated to diabetic patients with or without community pharmacist involvement.
    Foucault-Fruchard L; Bizzoto L; Allemang-Trivalle A; Renoult-Pierre P; Antier D
    Prim Health Care Res Dev; 2020 Nov; 21():e49. PubMed ID: 33155539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Use of DPP-4 Inhibitors.
    Gallwitz B
    Front Endocrinol (Lausanne); 2019; 10():389. PubMed ID: 31275246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a GPR40 Superagonist: The Impact of Aryl Propionic Acid α-Fluorination.
    Huang H; Meegalla SK; Lanter JC; Winters MP; Zhao S; Littrell J; Qi J; Rady B; Lee PS; Liu J; Martin T; Lam WW; Xu F; Lim HK; Wilde T; Silva J; Otieno M; Pocai A; Player MR
    ACS Med Chem Lett; 2019 Jan; 10(1):16-21. PubMed ID: 30655940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.